ClinicalTrials.gg

Program

GT801

A development code. Also written as “GT801 Injection”.

Its studies are mostly in Autoimmune Diseases · Burkitt Lymphoma, led by 2 companies.

Furthest: early phase 1, since Sep 25, 20253 company-led studies, 3 open or runningNext primary completion: Nov 30, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grit Biotechnology22 open or runningearly phase 1since Sep 25, 2025Sep 25, 2025Nov 30, 2027early phase 1 · NCT07205315
Vivacta Biotechnology (Shanghai)11 open or runningearly phase 1since May 13, 2026May 13, 2026Dec 30, 2031early phase 1 · NCT07614191

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 25, 2025First study: early phase 1 study in Burkitt LymphomaNew to Grit BiotechnologyGrit Biotechnology · NCT07205315 · 28 planned · China
  2. Dec 15, 2025Early phase 1 study in Moderate to Severe Refractory Autoimmune DiseaseGrit Biotechnology · NCT07333118 · 22 planned · China
  3. May 13, 2026Vivacta Biotechnology (Shanghai)'s first study: early phase 1 study in Moderate to Severe Refractory Autoimmune DiseasesNew to Vivacta Biotechnology (Shanghai)Vivacta Biotechnology (Shanghai) · NCT07614191 · 22 planned · China

Ahead

  1. Nov 30, 2027Primary completion: early phase 1 study in Burkitt LymphomaGrit Biotechnology · NCT07205315
  2. Mar 31, 2028Primary completion: early phase 1 study in Moderate to Severe Refractory Autoimmune DiseaseGrit Biotechnology · NCT07333118
  3. Dec 30, 2031Primary completion: early phase 1 study in Moderate to Severe Refractory Autoimmune DiseasesVivacta Biotechnology (Shanghai) · NCT07614191

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07614191Moderate to Severe Refractory Autoimmune Diseases · ChinaEarly 1RecruitingVivacta Biotechnology (Shanghai)Dec 30, 203122
NCT07333118Moderate to Severe Refractory Autoimmune Disease · ChinaEarly 1RecruitingGrit BiotechnologyMar 31, 202822
NCT07205315Burkitt Lymphoma · ChinaEarly 1RecruitingGrit BiotechnologyNov 30, 202728

How it is read

Names in the registry

  • “GT801 Injection”, 3 entries

Codes read as this program: GT801.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.